TOMO - U

Querétaro, México
August 15th to 19th, 2016
OVERVIEW

- **5 days training** – 2 trainings were provided consecutively

- **26 Wokstation with new Bellus2** (Spanish version) + BARCO monitors (12MP, 10MP, 2x5MP)

- **150 doctors** involved on this activity

- **Training #1 (English) - Dr Laszlo Tabar** - “Hands-on screening course combined with Multimodality Diagnosis of Breast Diseases” - 3 days training – 50 doctors – 175 cases – simultaneous Spanish translation.

- **Training #2 (Spanish) – TOMO U** – International Speakers (Dr Leborgne – Uruguay / Dr Palazuelos & Dr Romero – Colombia) - 2 days training – 100 doctors – 55 cases
Dr LASZLO TABAR - “Hands-on screening course combined with Multimodality Diagnosis of Breast Diseases”

- **Objective:** early stages cancer detection / screening oriented
- 3 days training – 50 doctors - 2 doctors per wkst – 175 cases – 15 hs hands-on effective time.
- FFDM 2D images were display on Bellus2.
- DICOM images were projected using DICOM Projector (Barco)
- MRI, US, Biopsy images projected for all the classroom.
- Lectures were provided separately.
TOMO U – Day #1 – 100 doctors - 6 hs hands-on

- Attendees read 35 cases utilizing only 2D images and filling out an electronic report on their own cell phones. After that, attendees completed a 2\textsuperscript{nd} report including 3D images.

- Speakers reviewed each case, with attendees participation, and evaluated the cases and shown the classroom statistic on each case, showing in-situ how 3D affected on their final diagnosis.
TOMO U – Day #2 – 100 doctors - 6 hs hands-on

- Attendees read 20 cases utilizing 2D + 3D images on each study. Speakers reviewed each one and group discussion.

- Other topics covered:
  1. “TOMO ONLY Pathology”, Innovality Tomo Biopsy.
  2. Synthetized Image.
  3. BIRADS update.
  4. Management: “How implement TOMO in LATAM. Real Case Discussion”. Items covered: Opportunity costs, epidemiology and statistics are shown in order to explain a persuasive way how to convince Hospital Board Members about TOMO implementation from clinical and finance point of view.